ESMO 23: Kelun/Merck, Hansoh ADCs Impress With Early Data In Breast Cancer

 
• By Dexter Jie Yan

In new data from Chinese developers at ESMO, Kelun/Merck’s Trop2-targeting ADC SKB264 (MK-2870) appears ready to hog the limelight from Daiichi Sankyo/AstraZeneca’s Dato-DXd, while Hansoh’s B7-H4-targeting HS-20089 is coming to the fore against its global same-class competitors. There were also new clinical results for Mabwell/Hengrui’s Nectin-4-targeting 9MW2821 and HER2-targeting SHR-A1811.

stage limelight
ESMO Congress turns spotlight on ADCs from Chinese developers • Source: Shutterstock

More from China

More from Focus On Asia